News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Nycomed Still Plans IPO
April 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH—Closely held pharmaceutical company Nycomed SCA Monday said it still plans to launch an initial public offering despite a U.S. advisory panel voting not to recommend its lung drug Daxas.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
October 2, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
The Top Big Pharmas Have $1.2T in Stretch M&A Firepower Available
October 1, 2025
·
6 min read
·
Annalee Armstrong
Mergers & acquisitions
Just 9.5% of Life Sciences M&A Milestones Have Been Paid Since 2008
October 1, 2025
·
2 min read
·
Annalee Armstrong
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
October 1, 2025
·
4 min read
·
Nick Paul Taylor
